Orlando, FL -- (SBWIRE) -- 10/10/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Gilead Sciences, Inc.(NASDAQ:GILD).
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares dropped 65.99% to $5.83. The company on Oct. 9 announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA). With a median follow up of 24 months, serious arterial thrombosis occurred in 11.8% of Iclusig-treated patients: cardiovascular events 6.2%, cerebrovascular events 4.0% and peripheral vascular events 3.6% (some patients had more than one type of event). This compares to 8.0% after 11 months of follow up reflected in the current U.S. prescribing information. At 24 months, serious venous occlusion occurred in 2.9% of Iclusig-treated patients, compared to 2.2% in the current U.S. prescribing information.
Are investors worried about the recent updates with ARIA? Find out with a free trend analysis HERE
Gilead Sciences, Inc.(NASDAQ:GILD) shares declined 0.81% to $58.90. The company on Oct. 9 said it will stop its Phase 3 study of a treatment for chronic lymphocytic leukemia as interim results have demonstrated significant efficacy for its primary endpoint. The treatment, which is called idelalisib, was being tested for patients not fit for chemotherapy. It demonstrated "highly statistically significant efficacy" in patients receiving the treatment receiving idelalisib plus rituximab compared with those receiving rituximab alone, the company said.
The company said it told the Food and Drug Administration of its plan to end the study early. It also said it plans to talk with the FDA about a regulatory filing for chronic lymphocytic leukemia treatment.
Is GILD going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)